To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR) adult patients at a single U.K. centre.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Patient baseline characteristics
Timeframe: At diagnosis
Grip strength test
Timeframe: At diagnosis or pre-Ig treatment initiation.
9-hole peg test
Timeframe: At diagnosis or pre-Ig treatment initiation.
10 meter walk test
Timeframe: At diagnosis or pre-Ig treatment initiation.
Overall neuropathy limitations scale
Timeframe: At diagnosis or pre-Ig treatment initiation.
Berg balance test
Timeframe: At diagnosis or pre-Ig treatment initiation.
Medical research council muscle strength score
Timeframe: At diagnosis or pre-Ig treatment initiation.
Inflammatory neuropathy cause and treatment (INCAT) sensory sum (ISS) score
Timeframe: At diagnosis or pre-Ig treatment initiation up to December 31, 2022 or death or lost-to-follow-up, whichever comes first.